Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug dosing during continuous arteriovenous hemofiltration.

S K Bickley1

  • 1Department of Pharmacy Services, University of Michigan Medical Center, Ann Arbor 48109.

Clinical Pharmacy
|March 1, 1988
PubMed
Summary

Continuous arteriovenous hemofiltration (CAVH) offers an alternative for acute renal failure management. This review details drug clearance during CAVH, aiding in dosage adjustments for intensive care settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician opinion of pharmacist-initiated change from injectable to oral administration of histamine H2-receptor antagonists.

American journal of hospital pharmacy·1991
Same author

Discontinuing antiepileptic therapy.

American family physician·1985
Same author

Stability of theophylline in human serum and whole blood.

American journal of hospital pharmacy·1984
See all related articles

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Acute renal failure (ARF) management often requires renal replacement therapy.
  • Continuous arteriovenous hemofiltration (CAVH) is an alternative to traditional dialysis methods.
  • Understanding drug clearance during CAVH is crucial for optimizing patient treatment.

Purpose of the Study:

  • To provide an overview of CAVH as a treatment for ARF.
  • To review existing literature on drug clearance during CAVH.
  • To discuss methods for estimating drug clearance and adjusting dosages.

Main Methods:

  • Literature review of studies on CAVH and drug clearance.
  • Explanation of convective mass transport and solute removal via extracorporeal filters.
  • Discussion of sieving coefficients and ultrafiltration rates in determining compound clearance.

Main Results:

  • CAVH removes non-protein-bound solutes smaller than 10,000 daltons via convection.
  • The system achieves a creatinine clearance of approximately 10 mL/min.
  • Clinically significant clearance of common intensive care drugs (e.g., aminoglycosides, vancomycin) is expected during CAVH.

Conclusions:

  • CAVH enhances the treatment of acute renal failure.
  • Drug clearance during CAVH is influenced by factors like sieving coefficient and ultrafiltration rate.
  • Dosage adjustments for medications can be guided by established methods, despite limited specific drug data.

Related Experiment Videos